Clinical Trial Update: Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. [Phase 3]

View source ↗

Summary

Phase 3 trial update on long-acting injectable cabotegravir for HIV PrEP in men who have sex with men in France; status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immune Deficiency Syndrome
• HIV Infection

Drugs mentioned

• CAB-LA (cabotegravir) long-acting injectable (cabotegravir)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Prevention | Phase 3 | Status: NOT_YET_RECRUITING